The role of growth hormone in the pathogenesis of diabetic kidney disease.
At present, diabetic kidney disease affects about 15-20% of all Type 1 diabetic patients and 20-40% of all patients with Type 2 diabetes. Preclinical research performed over the past decade has suggested growth hormone (GH) and insulin-like growth factors (IGFs) to be involved in the pathogenesis of diabetic kidney disease. Data obtained in knock-out (KO) mice with GH receptor (GHR)/GH binding protein (GHBP) gene-disruption have shown that these animals are protected against diabetes-induced renal changes. Further, diabetic mice treated with either a longacting somatostatin analogue or a specific GHR antagonist (GHRA) showed normalization of the diabetes-associated renal hypertrophy and glomerular enlargement and most importantly also a lowering effect on the diabetes-induced rise in urinary albumin excretion (UAE), a marker of renal damage. Based on these experimental data future studies are warranted to characterize the clinical potential of GH-inhibitors (e.g. GHRAs) as drugs for the treatment of diabetic renal complications.
Flyvbjerg
Allan
A
The Medical Research Laboratories, Clinical Institute, Medical Department M (Diabetes and Endocrinology), Aarhus University Hospital, Aarhus, Denmark. allan.flyvbjerg@dadlnet.dk
D000818:Animals; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D013006:Growth Hormone / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000187:drug effects / Q000378:metabolism; D015282:Octreotide / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011986:Receptors, Somatotropin / Q000037:antagonists & inhibitors; D013004:Somatostatin / Q000031:analogs & derivatives / Q000627:therapeutic use
C119223:G120K-PEG; C420459:PTR 3173; D011986:Receptors, Somatotropin; D011092:Polyethylene Glycols; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D015282:Octreotide